This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Scandion Oncology 過去の業績
過去 基準チェック /06
主要情報
-56.8%
収益成長率
-26.3%
EPS成長率
| Biotechs 業界の成長 | 0.7% |
| 収益成長率 | n/a |
| 株主資本利益率 | -60.8% |
| ネット・マージン | n/a |
| 次回の業績アップデート | 25 Aug 2022 |
最近の業績更新
更新なし
Recent updates
更新なし
収支内訳
収支内訳
Scandion Oncology の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 22 | 0 | -56 | 10 | 53 |
| 31 Dec 21 | 0 | -52 | 8 | 48 |
| 30 Sep 21 | 0 | -43 | 22 | 30 |
| 30 Jun 21 | 0 | -31 | 11 | 30 |
| 31 Mar 21 | 0 | -22 | 1 | 30 |
| 31 Dec 20 | 0 | -17 | 3 | 22 |
| 30 Sep 20 | 0 | -11 | 27 | 0 |
| 30 Jun 20 | 0 | -14 | 23 | 0 |
| 31 Mar 20 | 0 | -14 | 19 | 0 |
| 31 Dec 19 | 0 | -12 | 16 | 0 |
| 30 Sep 19 | 0 | -17 | 5 | 0 |
| 30 Jun 19 | 0 | -12 | 4 | 0 |
| 31 Mar 19 | 0 | -10 | 3 | 0 |
| 31 Dec 18 | 0 | -8 | 3 | 0 |
| 30 Sep 18 | 0 | -4 | 1 | 0 |
質の高い収益: SCOL BTA is currently unprofitable.
利益率の向上: SCOL BTA is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: SCOL BTA is unprofitable, and losses have increased over the past 5 years at a rate of 56.8% per year.
成長の加速: Unable to compare SCOL BTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: SCOL BTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.6%).
株主資本利益率
高いROE: SCOL BTA has a negative Return on Equity (-60.84%), as it is currently unprofitable.